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OBJECTIVES: The purpose of our study is to investigate whether the time of onset
of an acute cerebrovascular event demonstrates a seasonal variation, and we also
examined the influence of certain meteorological factors on the occurrence of this
event. METHODS: Patients admitted to the Departments of Neurology in Hungary
between 2005 and 2007 with the diagnosis of a cerebral hemorrhage (n11,604) or
a transient ischemic attack (n12,513) were examined. For data collection we used
the database of the Hungarian National Health Insurance Fund Administration
(OEP) on the basis of International Classification of Diseases (ICD). Meteorological
data (temperature, atmospheric pressure, relative humidity) was retrieved from
the National Meteorology Service. Statistical analysis was carried out with SPSS
14.0 for Windows. RESULTS: The analysis of meteorological data showed that an
increase in average temperature on the previous day resulted in a notable drop of
cerebral hemorrhage incidence during all seasons (p0.05), while in case of tran-
sient ischemic attack such a decrease only occurred during Summer (p0.05). We
have not found demonstrable influence while examining atmospheric pressure
and relative humidity. CONCLUSIONS: To summarize, we can say that our results
indicate that the incidence of cerebral infarction, cerebral hemorrhage, and a tran-
sient ischemic attack show a typical variation depending on the season of the year.
We can also say that the values of temperature may influence the development of
different cerebrovascular events.
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OBJECTIVES: To determine the population attributable risk (PAR) of macrovascular
events associated with HbA1c, systolic blood pressure (SBP), or weight (BMI) in
patients with type 2 diabetes mellitus (T2DM). METHODS: The population-based
PHARMO database contains T2DM patients regularly monitored in primary care for
cardiovascular risk factors HbA1c, SBP and BMI. In the period 2000-2008 patients
without baseline macrovascular events and on antidiabetic treatment for 6
months were followed from start of monitoring until monitoring ended. Multivar-
iate survival modeling of the composite outcome of macrovascular events was
used to estimate the expected number of events after 5 years, either with un-
changed risk factors (base-case) or with reductions in risk factors. The PAR was
calculated as the number of averted events divided by the number of expected
events in the base-case analysis. RESULTS:Mean age of 5841 included patients was
66 years (55% male), 45% had HbA1c levels 7%, 66% had a SBP 140 mmHg and
85% had a BMI25 kg/m2. The base case expected number of macrovascular events
at 5 years was 796, and 687 after reduction to target of all 3 risk factors. The com-
bined PAR of elevated HbA1c, SBP and BMI was 14%, ranging from 5% among those
with one elevated risk factor to 21% among those with three risk factors elevated.
Incremental reductions of 0.5% HbA1c, 10mmHg SBP and 10% BMI led to 4% fewer
events, ranging from 2-10%. The PAR of reducing HbA1c to target (7%) was 5%,
ranging from 2-10%. The PAR of reducing SBP to target (135 mmHg) was 9%, ranging
from 3-12%. There was no effect of reduction in BMI alone. CONCLUSIONS: Reduc-
ing elevated HbA1c and blood pressure levels was associated with improvements
in cardiovascular risk. Even modest reductions in risk factors lead to significant
reductions in macrovascular events in T2DM patients.
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OBJECTIVES: To report on the goal rates for SBP, plasma lipid variables, and body
mass index (BMI), based on published guidelines, from data available in the 2nd
quarter (Q2) post-baseline of the GVRM initiative; a 5-year project focusing on
validating the COSEHC risk score through cardiovascular risk factor management.
METHODS: The Consortium for Southeastern Hypertension Control (COSEHC) de-
veloped a risk score tool to predict cardiovascular disease (CVD) mortality in the
southeastern (SE) US. This global approach to SE CVD calculates the absolute risk
for 5-year CVD mortality based on: age, sex, total, HDL and LDL-cholesterol, trig-
lycerides (TG), SBP, and evidence of smoking, diabetes, family history of CHD, and
ECG-confirmed cardiac hypertrophy. Baseline data were obtained from 78,540 pa-
tients (42,707 females) across ten medical facilities. RESULTS: From 39,080 females
and 33,144 males with Q2 data at goal for SBP (63 vs. 70%), LDL-cholesterol (41 vs. 55
%), TG (59 vs. 57%), and % of non-smokers were similar between the two sexes.
Female subjects, however, achieved higher at goal targets for HDL-cholesterol (63
vs. 36% in males, p 0.05) and BMI (22 vs. 16 in males, p 0.003). In addition, at goal
rates for SBP control correlated with improved HDL-cholesterol (r0.64, p 0.05)
and weight values in females (r -0.69, p 0.05) and only weight in males (r -0.76,
p  0.05). COSEHC 5-year absolute risk scores for CVD mortality in the entire pop-
ulation were higher in males [(Mean SD) 36.43 2.26] compared to females (30.57
 3.38, p  0.0005). CONCLUSIONS: The GVRM initiative provides an effective way
of benchmarking risk factors in a population at high risk for cardiovascular events.
The initiative is assisting health care providers to monitor risk factors at regular
intervals and proactively manage the cardiovascular risk of their patient popula-
tion.
PCV35
SAFETY AND TOLERABILITY OF BISOPROLOL COMPARED TO ATENOLOL IN
PATIENTS WITH MILD TO MODERATE HYPERTENSION
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OBJECTIVES: The objective was to evaluate the safety and tolerability of bisoprolol
compared to atenolol in patients with essential mild to moderate hypertension.
METHODS: Studies were retrieved from Embase, Pubmed, and Cochrane databases
using relevant search strategies. Randomised controlled trials which compared
bisoprolol with atenolol were included according to pre-specified inclusion/exclu-
sion criteria. The outcomes of interest were total withdrawals from study, with-
drawals due to adverse events (AE), withdrawals due to lack of efficacy, any adverse
events, bradycardia, fatigue, oedema and vertigo. Two reviewers independently
extracted data from the included studies. Data was meta-analysed using RevMan
(5). RESULTS:Of the 1056 studies identified, 11 studies met the inclusion criteria. In
total, 624 patients were randomised to bisoprolol, and 683 were randomised to
atenolol. Seven of the included studies were double-blind, three were single-blind
and one was open-label study. The Jadad score of eight studies was3 and were of
good quality. The study duration of included studies ranged from 8-weeks to 52-
weeks. Results of meta-analysis showed that with bisoprolol there was lower risk
of study withdrawals [RR: 0.95 (0.79, 1.16)] and withdrawals due to lack of efficacy
[RR: 0.58 (0.14, 2.37)] as compared to atenolol. Withdrawals due to AE were more in
the bisoprolol group compared to atenolol. The risk of AE (any) was lower with
atenolol compared to atenolol [RR: 0.94 (0.73, 1.21)]. The risk of bradycardia was
higher with bisoprolol compared to atenolol (p0.3). Lower risk of oedema (p0.3)
and vertigo (p0.6) was reported with bisoprolol as compared to atenolol.
CONCLUSIONS: This review has included the evidence to date with regards to
safety and tolerability of bisoprolol compared to atenolol. This review concludes
that availability of bisoprolol provides the patients with a safe and efficacious
first-line therapy option in hypertension.
PCV36
HIGH DOSE AND LONG-TERM SAFETY OF SYSTEMIC CORTICOSTEROIDS IN THE
TREATMENT OF POLYMYLAGIA RHEUMATICA AND VASCULITIS: A
SYSTEMATIC REVIEW
Nyssen OP1, Gauthier A1, Schmitt C2, Levy V2, Cognet M1, Aguiar-ibanez R1
1Amaris Consulting UK, London, UK, 2GlaxoSmithKline, London, UK
OBJECTIVES: To review the evidence base for the safety of high dose and long-term
usage of systemic corticosteroids (CSs). METHODS: Selection of studies: popula-
tion-based studies involving patients with polymyalgia rheumatica or vasculitis
treated with systemic CSs and reporting the incidence of diabetes, hypertension,
cataract, osteoporosis or cardiovascular events. Search strategy: A systematic lit-
erature review was conducted in Medline, Medline-in-process, Embase, and the
Cochrane Library up to January 2011, with very broad search terms in order to limit
the risk of missing relevant studies. Data synthesis: “Key studies” were identified as
assessing comparisons relevant to our study question (CSs vs. no use of CSs and/or
assessment of CSs at different doses) and reporting at least one outcome of interest
by treatment group. Results were summarized separately for key studies and other
studies. RESULTS: Out of 3671 citations initially identified for screening 76 publi-
cations were selected. Few studies were identified as key: only 3 reported the inci-
dence of diabetes, hypertension or cardio-vascular events, four studies docu-
mented the development of cataract and seven reported outcomes related to
osteoporosis. Based on these studies, outcomes such as cataract and osteoporosis
presented a higher rate of incidence for both indications within the CSs treatment
groups, and tended to be less common when the treatment arm combined intra-
venous or intramuscular CSs with oral CSs than with oral CSs alone. No significant
association was found for the other outcomes of interest. The magnitude of the CSs
effect on the outcomes of interest varied greatly between studies. CONCLUSIONS:
Although CSs are a cornerstone of treating polymyalgia rheumatica and vasculitis,
the evidence base for their safety profile is poor, subject to a high level of hetero-
geneity, and the findings for the different outcomes were not always consistent
across studies, demonstrating the need for further research in this area.
PCV37
PARAMETRIC CONDITIONAL NON-FRAILTY MODEL FOR RECURRENT EVENTS IN
PERSONS WITH TYPE 2 DIABETES IN SWEDEN: THE EXAMPLE OF MYOCARDIAL
INFARCTION
Ahmad Kiadaliri A1, Clarke PM2, Gerdtham UG1, Nilsson P1, Eliasson B3,
Gudbjörnsdottir S3, Steen carlsson K1
1Lund University, Malmö, Skane, Sweden, 2University of Sydney, Sydney, Sydney, Australia,
3University of Gothenburg, Göteborg, Göteborg, Sweden
OBJECTIVES: The risk of subsequent events after a first cardiovascular event in
persons with type 2 diabetes has received less attention to date. Simulation mod-
els, including risk engines and health-economic cost-effectiveness models, have
thus relied primarily on estimations of the risk of first events and assumed con-
stant transition probabilities for subsequent events. The aim of the current study is
to analyze the differences in risk of having a first and a second myocardial infarc-
tion (MI) for persons with type 2 diabetes. METHODS: Observational data from the
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